2020 was an extraordinary year unlike any other. The sudden outbreak of COVID-19 profoundly reshaped global politics, economies, and people’s daily lives, accelerating the arrival of a "great shift unseen in a century." Looking back on 2020, Jiuzhitang advanced hand-in-hand with the times, stood firmly by the nation, and moved forward with unwavering determination, achieving remarkable milestones: Facing the pandemic, Jiuzhitang swiftly resumed production and operations, ensuring stable pricing, uninterrupted supply, and uncompromising quality—while also donating funds and supplies to support frontline anti-epidemic efforts, actively contributing to the fight against the virus. Meanwhile, by reaffirming its commitment to clinical value and embracing culturally driven marketing strategies, the company successfully navigated the challenges posed by the pandemic, maintaining steady growth in both production and sales. Innovation continued to flourish as well: Jiuzhitang secured approval for its groundbreaking therapy using bone marrow mesenchymal stem cells to treat ischemic stroke, marking a significant leap forward; meanwhile, its innovative anticoagulant drug candidate LFG and other promising projects like 477 are progressing smoothly, further bolstering the company’s internal momentum. Additionally, Jiuzhitang made strategic strides by launching its official online hospital platform, boldly entering the digital healthcare space and enhancing its ability to thrive in both domestic and international markets—a move that aligns seamlessly with the "dual circulation" strategy.On the brand front, Jiuzhitang earned recognition as one of the first "International/Standardized National Brand Evaluation Application Demonstration Units," while also securing prestigious spots on lists such as the "Top 100 Chinese Pharmaceutical Companies," the "China Time-Honored Brands Ranking," and the "Top 100 Traditional Chinese Medicine Enterprises." These accolades highlight the company’s growing influence and reputation, further cementing its position as a trusted leader in the industry. With unwavering dedication and relentless perseverance, Jiuzhitang has steadily advanced across all fronts, delivering outstanding achievements and paving the way for even greater success in the years ahead.

2020 was an extraordinary year like no other. The sudden outbreak of COVID-19 profoundly impacted global politics, economies, and people’s daily lives, accelerating the arrival of a "great shift unseen in a century." Looking back on 2020, Jiuzhitang advanced hand-in-hand with the times, stood firmly with the nation, and pressed forward with determination, achieving remarkable milestones: Facing the pandemic, Jiuzhitang swiftly resumed production and operations, ensuring stable pricing, uninterrupted supply, and unwavering quality—while also donating funds and supplies to support frontline抗疫 efforts, actively contributing to the fight against the virus. Meanwhile, by recommitting to clinical value and embracing culturally driven marketing strategies, the company successfully navigated the challenges posed by the pandemic, maintaining steady growth in both production and sales. Innovation continued to thrive as well: Jiuzhitang secured approval for its groundbreaking therapy using bone marrow mesenchymal stem cells to treat ischemic stroke, marking a significant leap forward; meanwhile, its innovative anticoagulant drug candidate LFG and other promising projects like 477 are progressing smoothly, further strengthening the company’s internal momentum. Additionally, Jiuzhitang made strategic strides by launching its official online hospital platform, boldly entering the digital healthcare space and boosting its ability to thrive in both domestic and international markets—a move that aligns seamlessly with the "dual circulation" strategy. On the brand front, Jiuzhitang earned recognition as one of the first "International/Standardized National Brand Evaluation Application Demonstration Units," while also securing prestigious spots on lists such as the "Top 100 Chinese Pharmaceutical Companies," the "China Time-Honored Brands Ranking," and the "Top 100 Traditional Chinese Medicine Enterprises." These accolades underscore the company’s growing influence and reputation, further solidifying its position as a trusted leader in the industry. With unwavering dedication and relentless perseverance, Jiuzhitang has steadily advanced across all fronts, delivering outstanding achievements and setting the stage for even greater success in the years ahead.

The old year has already unfurled a thousand layers of vibrant brocade, and the new year calls us to climb another hundred feet higher. 2021 marks the beginning of our ambitious journey toward the "14th Five-Year Plan" and the pursuit of new dreams. In a world where countless boats race forward—those that don’t advance risk being left behind. The blueprint for the "14th Five-Year Plan" has already been drawn up, and 2021 is now setting sail. Upholding our corporate mission of "A Century of Jiuzhitang, Serving Greater Health," let’s stay steadfast in our confidence, join forces, and move forward together. Guided by the Group’s strategic goals, we’ll remain grounded, take proactive steps, and deliver high-quality products and services tailored to meet the holistic health management needs of people across their entire life cycle. By fostering both domestic and international resource flows—a dual "dual circulation"—we’ll build Jiuzhitang’s unique ecosystem for innovative health services. Let’s ignite our dreams with passion, turn aspirations into reality through dedicated action, and steadily climb toward new heights in Jiuzhitang’s ongoing journey of growth. Together, we’ll write a fresh chapter of high-quality development for Jiuzhitang!

Finally, I sincerely wish everyone career advancement, happiness and joy for your families, and good health and well-being!

Li Zhenguo, President of Jiuzhitang Group

January 1, 2021